Evidence map›Paper›PMID 38052461›Full record

ArticleLife science alliance2024

Proteomic-based stratification of intermediate-risk prostate cancer patients.

Qing Zhong, Rui Sun, Adel T Aref, Zainab Noor, Asim Anees, Yi Zhu, Natasha Lucas, Rebecca C Poulos, Mengge Lyu, Tiansheng Zhu and 20 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Hypoxia-induced circ_0017521 enhances glycolysis and promotes NSCLC progression via upregulating the PFKFB3/PI3K-AKT pathway.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 11 institutions in 4 countries.

Qing ZhongProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID https://orcid.org/0000-0002-5340-301X
Rui SuniMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
Adel T ArefProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID https://orcid.org/0000-0003-3028-131X
Zainab NoorProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
Asim AneesProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
Yi ZhuiMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
Natasha LucasProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID https://orcid.org/0000-0002-7656-6866
Rebecca C PoulosProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
Mengge LyuiMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
Tiansheng ZhuiMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
Guo-Bo ChenUrology & Nephrology Center, Department of Urology, Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.ORCID https://orcid.org/0000-0001-5475-8237
Yingrui WangiMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
Xuan DingiMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
Dorothea RutishauserDepartment of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland.ORCID https://orcid.org/0000-0003-2303-103X
Niels J RuppDepartment of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland.
Jan H RueschoffDepartment of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland.
Cédric PoyetDepartment of Urology, University Hospital Zürich, Zürich, Switzerland.ORCID https://orcid.org/0000-0002-3648-6941
Thomas HermannsDepartment of Urology, University Hospital Zürich, Zürich, Switzerland.
Christian FankhauserDepartment of Urology, University Hospital Zürich, Zürich, Switzerland.
María Rodríguez MartínezIBM Zürich Research Laboratory, Zürich, Switzerland.ORCID https://orcid.org/0000-0003-3766-4233
Wenguang ShaoState Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Marija BuljanEmpa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland.
Janis Frederick NeumannCECAD, University of Cologne, Cologne, Germany.
Andreas BeyerCECAD, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-3891-2123
Peter G HainsProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID https://orcid.org/0000-0002-7276-1760
Roger R ReddelProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID https://orcid.org/0000-0002-6302-6107
Phillip J RobinsonProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.
Ruedi AebersoldDepartment of Biology, Institute of Molecular Systems Biology, ETH Zürich, Zürich, Switzerland aebersold@imsb.biol.ethz.ch.ORCID https://orcid.org/0000-0002-9576-3267
Tiannan GuoiMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China guotiannan@westlake.edu.cn.ORCID https://orcid.org/0000-0003-3869-7651
Peter J WildGoethe University Frankfurt, Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt am Main, Germany peter.wild@ukffm.de.ORCID https://orcid.org/0000-0002-1017-3744
The University of Sydney · AUWestlake University · CNUniversity Hospital of Zurich · CHUniversity of Cologne · DEGoethe University Frankfurt · DEIBM Research - Zurich · CHShanghai Jiao Tong University · CNSIB Swiss Institute of Bioinformatics · CHUniversity of Lucerne · CHUniversity of Zurich · CHZhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gleason grading is an important prognostic indicator for prostate adenocarcinoma and is crucial for patient treatment decisions. However, intermediate-risk patients diagnosed in the Gleason grade group (GG) 2 and GG3 can harbour either aggressive or non-aggressive disease, resulting in under- or overtreatment of a significant number of patients. Here, we performed proteomic, differential expression, machine learning, and survival analyses for 1,348 matched tumour and benign sample runs from 278 patients. Three proteins (F5, TMEM126B, and EARS2) were identified as candidate biomarkers in patients with biochemical recurrence. Multivariate Cox regression yielded 18 proteins, from which a risk score was constructed to dichotomize prostate cancer patients into low- and high-risk groups. This 18-protein signature is prognostic for the risk of biochemical recurrence and completely independent of the intermediate GG. Our results suggest that markers generated by computational proteomic profiling have the potential for clinical applications including integration into prostate cancer management.

Indexed as

Prostatic NeoplasmsProteomicsHumansMaleNeoplasm GradingRisk Factors

Identifiers

PMID38052461
PMCPMC10698198
OpenAlexW4389343509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.